NASDAQ:CDXC ChromaDex (CDXC) Stock Price, News & Analysis $3.33 +0.07 (+2.15%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.13▼$3.3650-Day Range$2.51▼$3.5152-Week Range$1.25▼$4.65Volume249,120 shsAverage Volume305,210 shsMarket Capitalization$251.54 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get ChromaDex alerts: Email Address ChromaDex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.2% Upside$6.00 Price TargetShort InterestBearish6.76% of Float Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$82,110 Sold Last QuarterProj. Earnings Growth800.00%From $0.01 to $0.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.72 out of 5 starsMedical Sector210th out of 910 stocksMedicinals & Botanicals Industry1st out of 12 stocks 3.5 Analyst's Opinion Consensus RatingChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChromaDex has only been the subject of 2 research reports in the past 90 days.Read more about ChromaDex's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.76% of the float of ChromaDex has been sold short.Short Interest Ratio / Days to CoverChromaDex has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in ChromaDex has recently increased by 3.53%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldChromaDex does not currently pay a dividend.Dividend GrowthChromaDex does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChromaDex has received a 59.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Dietary supplements" products. See details.Environmental SustainabilityThe Environmental Impact score for ChromaDex is -1.65. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for ChromaDex this week, compared to 1 article on an average week.Search Interest3 people have searched for CDXC on MarketBeat in the last 30 days. MarketBeat Follows3 people have added ChromaDex to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChromaDex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,110.00 in company stock.Percentage Held by InsidersOnly 9.64% of the stock of ChromaDex is held by insiders.Percentage Held by InstitutionsOnly 15.41% of the stock of ChromaDex is held by institutions.Read more about ChromaDex's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ChromaDex are expected to grow by 800.00% in the coming year, from $0.01 to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChromaDex is -66.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChromaDex is -66.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChromaDex has a P/B Ratio of 8.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ChromaDex's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About ChromaDex Stock (NASDAQ:CDXC)ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Read More CDXC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXC Stock News HeadlinesAugust 27, 2024 | insidertrades.comInsider Selling: ChromaDex Co. (NASDAQ:CDXC) Director Sells 23,000 Shares of StockAugust 29, 2024 | americanbankingnews.comInsider Selling: ChromaDex Co. (NASDAQ:CDXC) Director Sells $82,110.00 in StockSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 19, 2024 | finance.yahoo.comChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Chromadex’s Turnaround and Growth ProspectsAugust 8, 2024 | finanznachrichten.deChromaDex Corporation Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | msn.comChromaDex GAAP EPS of $0.00 beats by $0.01, revenue of $22.7M misses by $0.76MAugust 8, 2024 | seekingalpha.comChromaDex Corporation (CDXC) Q3 2024 Earnings Call TranscriptSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 6, 2024 | finance.yahoo.comChromaDex to Present at Canaccord Genuity’s 44th Annual Growth ConferenceJuly 30, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Chromadex (CDXC), Tarsus Pharmaceuticals (TARS)July 23, 2024 | finance.yahoo.comChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)July 22, 2024 | businesswire.comChromaDex Appoints Carlos Lopez as Senior Vice President, General CounselJune 24, 2024 | businesswire.comMilestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)June 13, 2024 | businesswire.comChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)June 7, 2024 | businesswire.comChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)June 4, 2024 | businesswire.comChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024May 27, 2024 | msn.comCompare with Chromadex Corp (CDXC)See More Headlines Receive CDXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2023Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDXC CUSIPN/A CIK1386570 Webwww.chromadex.com Phone(310) 388-6706Fax949-419-0294Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+80.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E Ratio333.00 P/E GrowthN/ANet Income$-4,940,000.00 Net Margins-1.58% Pretax Margin-1.58% Return on Equity-4.68% Return on Assets-2.50% Debt Debt-to-Equity RatioN/A Current Ratio2.76 Quick Ratio2.12 Sales & Book Value Annual Sales$85.58 million Price / Sales2.94 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book8.33Miscellaneous Outstanding Shares75,539,000Free Float68,257,000Market Cap$251.54 million OptionableOptionable Beta1.87 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Frank Louis Jaksch Jr. (Age 56)Co-Founder & Chairman Comp: $70kMr. Robert N. Fried (Age 64)CEO & Director Comp: $768.96kMs. Brianna Gerber (Age 43)Chief Financial Officer Comp: $482.15kDr. Andrew Shao Ph.D.Senior Vice President of Global Regulatory & Scientific AffairsHeather Van BlarcomSenior VP of Legal & Corporate SecretaryAlex WorshamVice President of Global Marketing & CommunicationsMr. David KroesSenior Vice President of People MattersMs. Chu YanManaging Director of Asia PacificMr. Jason CampbellSenior Vice President of Business DevelopmentKendall KnyschHead of Media Relations & PartnershipsMore ExecutivesKey CompetitorsMenlo TherapeuticsNASDAQ:FOMXMediWoundNASDAQ:MDWDNatural Alternatives InternationalNASDAQ:NAIIMannatechNASDAQ:MTEXUSANA Health SciencesNYSE:USNAView All CompetitorsInsiders & InstitutionsKristin PatrickSold 23,000 sharesTotal: $82,110.00 ($3.57/share)The Manufacturers Life Insurance Company Bought 11,247 shares on 8/15/2024Ownership: 0.015%Marshall Wace LLPBought 20,577 shares on 8/14/2024Ownership: 0.027%Merriman Wealth Management LLCBought 11,800 shares on 8/13/2024Ownership: 0.016%Tieton Capital Management LLCSold 53,815 shares on 8/10/2024Ownership: 3.929%View All Insider TransactionsView All Institutional Transactions CDXC Stock Analysis - Frequently Asked Questions How have CDXC shares performed this year? ChromaDex's stock was trading at $1.43 at the beginning of 2024. Since then, CDXC shares have increased by 132.9% and is now trading at $3.33. View the best growth stocks for 2024 here. How were ChromaDex's earnings last quarter? ChromaDex Co. (NASDAQ:CDXC) issued its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business earned $21 million during the quarter, compared to analysts' expectations of $21.08 million. ChromaDex had a negative net margin of 1.58% and a negative trailing twelve-month return on equity of 4.68%. What is Robert Fried's approval rating as ChromaDex's CEO? 13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend. Who are ChromaDex's major shareholders? ChromaDex's top institutional shareholders include Tieton Capital Management LLC (3.93%), Renaissance Technologies LLC (0.55%), WINTON GROUP Ltd (0.29%) and Bank of New York Mellon Corp (0.25%). Insiders that own company stock include Hoi Shuen Solina Holly Chau, Frank L Jaksch Jr, Robert N Fried, Brianna Gerber, Steven D Rubin and Kristin Patrick. View institutional ownership trends. How do I buy shares of ChromaDex? Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ChromaDex own? Based on aggregate information from My MarketBeat watchlists, some other companies that ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB) and Tilray (TLRY). This page (NASDAQ:CDXC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ChromaDex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
